Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : Veklury Lowers Hospitalization Risk in COVID-19 Patients in Phase 3 Study

09/22/2021 | 12:04pm EDT


ę MT Newswires 2021
All news about GILEAD SCIENCES, INC.
10/15GILEAD SCIENCES : Says Breast Cancer Therapy Receives Positive Opinion by European Medicin..
MT
10/15GILEAD SCIENCES : Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for..
BU
10/15Gilead's Sacituzumab Govitecan Gets Positive CHMP Opinion in Breast Cancer
DJ
10/14GILEAD SCIENCES : to Release Third Quarter 2021 Financial Results on Thursday, October 28,..
BU
10/14VC DAILY : Sprinter Health Collects $33 Million to Join Home-Healthcare Race
DJ
10/13PRESS RELEASE : NanoViricides, Inc. Has Filed its -2-
DJ
10/13PRESS RELEASE : NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program ..
DJ
10/12GILEAD SCIENCES : Morgan Stanley Adjusts Gilead Sciences PT to $84 from $83, Keeps Overwei..
MT
10/11EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation
RE
10/11REGENERON PHARMACEUTICALS : Merck seeks first U.S. authorization for COVID-19 pill
RE
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 25 103 M - -
Net income 2021 6 563 M - -
Net Debt 2021 23 120 M - -
P/E ratio 2021 13,4x
Yield 2021 4,18%
Capitalization 84 795 M 84 795 M -
EV / Sales 2021 4,30x
EV / Sales 2022 4,24x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 67,63 $
Average target price 76,35 $
Spread / Average Target 12,9%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156
BEIGENE, LTD.38.72%33 452